Patents by Inventor Thierry CHAMPION

Thierry CHAMPION has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10858423
    Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 8, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Alexandra Jouhanneaud, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Jean-Fran├žois Haeuw, Ian Rilatt, Michel Perez, Marie Lamothe
  • Publication number: 20200270352
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
  • Patent number: 10633448
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 28, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
  • Patent number: 10605315
    Abstract: A brake includes a caliper overlapping a disk. The brake also includes a first pad and a second pad which are carried by the caliper on either side of the disk. The brake further includes a first actuator including a first primary toothed wheel driving a first mobile piston pressing against the first pad in order to move same. The brake further includes a second actuator including a second primary toothed wheel driving a second mobile piston pressing against the second pad. The brake further includes a rotating shaft including a first and a second endless screw having opposite winding directions, the shaft being movable in translation. The brake further includes an electric motor for driving the rotating shaft. The first and second endless screws are engaged in the first and second primary toothed wheels respectively.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: March 31, 2020
    Assignee: FOUNDATION BRAKES FRANCE
    Inventors: Didier Esnee, Thierry Pasquet, Pascal Champion
  • Publication number: 20190330353
    Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 31, 2019
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane GOETSCH, Matthieu Broussas, Charlotte BEAU-LARVOR, Thierry Champion, Alain Robert
  • Publication number: 20190202901
    Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    Type: Application
    Filed: October 26, 2016
    Publication date: July 4, 2019
    Inventors: Alexandra JOUHANNEAUD, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Robert ALAIN, Jean-Fran├žois HAEUW, Ian RILATT, Michel PEREZ
  • Patent number: 10202458
    Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 12, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert
  • Publication number: 20170267766
    Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Application
    Filed: April 27, 2015
    Publication date: September 21, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane GOETSCH, Matthleu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Alain ROBERT
  • Publication number: 20170043031
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Mathieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT